Search clinical trials for: Imatinib

Total 1408 results

First People's Hospital of Hangzhou

Unknown

Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer

Esophageal Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Esophageal Carcinoma | Adenocarcinoma of the Gastroesophageal Junction

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Non-Small Cell Lung Cancer | Brain Metastases
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency

Non-small Cell Lung Cancer

China
Lei Li

Completed

First-line Chemotherapy for Recurrent Cervical Cancer

Chemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 Inhibitor

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation (ICAPE)

Non-small Cell Lung Cancer

China
Versailles Hospital

Completed

A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML (OPTIMIMATINIB)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

France
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment

Non-small Cell Lung Cancer

China
Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Withdrawn

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Choroidal Neovascularization

United States
The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
Huazhong University of Science and Technology

Unknown

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Gastric Cancer

China
Northwestern University
Allergan

Completed

Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure

Intraocular Pressure | Nail Growth Cessation

United States
Duke University
National Cancer Institute (NCI)

Completed

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Brain and Central Nervous System Tumors

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
Meng Li

Unknown

Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia (SESPI)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Peking Union Medical College Hospital

Completed

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Thyroid Cancer

China
Medical University of Silesia
Centrum Medyczne Andrzej Bożek

Not yet recruiting

Biologics and Sublingual Immunotherapy (BSIPL)

Asthma, Allergic
Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Recruiting

Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Centre Leon Berard

Recruiting

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)

Metastatic Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST) | Locally Advanced Gastrointestinal Stromal Tumor (GIST)

France
Samsung Medical Center

Completed

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Stomach Neoplasms

Korea, Republic of
University of Chicago
National Cancer Institute (NCI)

Recruiting

Afatinib in Advanced Refractory Urothelial Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral Cancer

United States
Ruijin Hospital

Active, not recruiting

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Shoucheng Ma

Unknown

Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients

Colorectal Neoplasms

China
First Affiliated Hospital, Sun Yat-Sen University

Completed

The Long-term Efficacy of Imatinib With Hepatic Resection or Other Local Treatment for GIST Liver Metastases

Liver Metastases | GIST, Malignant

China
Istituto Clinico Humanitas

Completed

Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

Mesothelioma, Malignant

Italy
National Cancer Institute (NCI)

Completed

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Annick Desjardins
AstraZeneca; Novartis Pharmaceuticals

Completed

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Glioblastoma | Gliosarcoma

United States
Novartis

Terminated

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Recurrent Glioblastoma Multiforme (GBM)

United States
Pfizer

Terminated

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

United States, Korea, Republic of, Spain, United Kingdom, Italy, Germany, Hong Kong
Beijing Hospital
Chinese Society of Clinical Oncology

Recruiting

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Solid Tumor

China
Centre Leon Berard
Boehringer Ingelheim

Completed

Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck (BIBW2992ORL)

Head and Neck Squamous Cell Carcinoma

France
Fuda Cancer Hospital, Guangzhou

Completed

Cryotherapy Combine Icotinib for Advanced NSCLC Treatment

Lung Neoplasms
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (ALTER-L004)

Non Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma (ICWIP)

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Guangdong Association of Clinical Trials
Guangdong Provincial People's Hospital

Completed

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer (BRAIN)

Non Small Cell Lung Cancer | Brain Metastasis

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Carcinoma, Non-Small-Cell Lung

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Kidney Cancer

United States
Gruppo Italiano MEsotelioma

Unknown

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Mesothelioma

Italy
Seoul National University Hospital

Terminated

Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children

Chronic Graft-versus-host Disease

Korea, Republic of
Peking University

Unknown

To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.

GIST

China
Novartis Pharmaceuticals

Completed

Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Chronic Myeloid Leukemia (CML)

Korea, Republic of
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Commissie Voor Klinisch Toegepast Onderzoek

Unknown

Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia

Leukemia

Netherlands, Belgium

Search clinical trials for: Imatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations